FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking ...
FibroGen, Inc. (trading historically under the ticker symbol FGEN on NASDAQ Global Select) is a biopharmaceutical company focused on discovering, developing, and bringing to market treatments for conditions where effective options remain limited. The company is headquartered at 409 Illinois Street, San Francisco, CA, and operates with a relatively small workforce (about 34 full-time employees reported in the provided data), consistent with the lean operating model commonly seen in clinical-stage biotechnology.
From a business and product perspective, FibroGen’s pipeline centers on two notable programs. Roxadustat (an orally administered small molecule) targets hypoxia-inducible factor (HIF) prolyl hydroxylases to address anemia associated with chronic kidney disease. According to the provided overview, roxadustat has completed Phase III trials in the US, Europe, China, and Japan for chronic kidney disease-related anemia, and it was described as advancing in China for anemia linked to myelodysplastic syndromes (Phase II/III). This positioning indicates a strategy of moving a single mechanistic platform through multiple anemia and blood-disorder contexts.
The second major program is pamrevlumab, a human monoclonal antibody that blocks connective tissue growth factor (CTGF). The company has described Phase III development efforts spanning idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with an additional Phase III trial underway for Duchenne muscular dystrophy. This reflects a broader platform approach: leveraging a targeted biologic to expand across fibrotic and oncology-adjacent indications, potentially enabling differentiated clinical development plans and partnership opportunities.
FibroGen’s execution model also includes strategic collaborations with large pharma partners, specifically Astellas Pharma and AstraZeneca, as indicated in the supplied description. Such collaborations can reduce risk, share development costs, and support global commercialization capabilities.
On financial and cost-related considerations, the provided dataset includes a range and valuation metrics (e.g., market capitalization, trading range, and profitability ratios) that are typical of a biotech company where revenue can be limited early on but development spending and working capital dynamics remain central. While the dataset includes many TTM ratios and margins, they primarily suggest the company’s investment and operating profile characteristic of biopharma development cycles rather than a mature, fully commercial cash-flow business.
Leadership is identified as Thane Wettig (CEO), with the company founded in 1993. Finally, the provided materials note that FibroGen rebranded to Kyntra Bio in 2026 and shifted its ticker to KYNB; nonetheless, the underlying therapeutic programs and corporate history in the FGEN period form the basis of this profile.
Manila Electric Company (MERALCO)PSE:MERWholesale Electricity Spot Market (WESM)National Grid Corporation of the PhilippinesElectricity Distribution Utilities (Various)Retail Electricity Suppliers (RES)
Proxies
4
First Philippine Holdings CorporationPSE:FPHEnergy Development CorporationDelistedManila Electric CompanyPSE:MEROrmat Technologies Inc.NYSE:ORA
